A phase II open-label study of olutasidenib post-transplant maintenance therapy for patients with IDH1-mutated myeloid malignancies.

Authors: Jeremy L. Ramdial, Kelly Sharon Chien, Ruitao Lin, Jennie Thy Duong, Rohtesh S. Mehta, Betul Oran, Uday R. Popat, Partow Kebriaei, Katy Rezvani, Gheath Alatrash, George Chen, Yago Nieto, Abhishek Maiti, Nicholas James Short, Ghayas C. Issa, Gautam Borthakur, Hagop M. Kantarjian, Richard E. Champlin, Elizabeth J. Shpall, Courtney Denton Dinardo

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps6583

Source: Full article

---

Abstract

TPS6583